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Delamanid and Bedaquiline Resistance in
Mycobacterium tuberculosis Ancestral Beijing
Genotype Causing Extensively Drug-Resistant
Tuberculosis in a Tibetan Refugee
To the Editor:
International efforts in ﬁghting tuberculosis (TB) have achieved a
drop in global TB mortality and prevalence rates by 45 and 41%,
respectively. Now, the yearly emergence of 450,000 cases of
multidrug-resistant (MDR)-TB, deﬁned by resistance to at least
rifampicin and isoniazid, is endangering TB control, particularly in
Asia and Eastern Europe (1). The approval of bedaquiline (Sirturo;
Janssen-Cilag International NV, Beerse, Belgium) by the U.S.
Food and Drug Administration (2012) and the European
Medicines Agency (2014), and of delamanid (Deltyba; Otsuka
Novel Products GmbH, Munich, Germany) by the European
Medicines Agency (2014), as new anti-TB drugs raised hope for
getting the MDR-TB epidemic under control (2). These drugs
have been proven to accelerate culture reversion and to improve
clinical outcome in MDR-TB (3, 4).
By the end of 2014, the ﬁrst TB case infected by an isolate with
bedaquiline resistance was reported (5). This patient, a 38-year-old
Tibetan refugee, was diagnosed in January 2011 with MDR-TB. He
received a combination treatment with cycloserine, capreomycin,
and para-aminosalicylic acid (PAS) and ethambutol plus
bedaquiline under compassionate use for 6 months. After
24 months, treatment was terminated. Five months later, the
patient experienced a relapse. The new isolate exhibited resistance
to clofazimine with a corresponding mutation in the Rv0678
regulator gene (2 T.C leading to M1A), which had been previously
demonstrated to result in cross-resistance to bedaquiline (6).
On the basis of these ﬁndings, a new treatment regimen was
started in August 2013, with PAS, capreomycin, ethambutol,
cycloserine, clofazimine (until October 2014), co-trimoxazole, and
inhaled amikacin, but sputum smears remained positive for acid-
fast bacilli. In March 2014, therapy was changed to a combination
of PAS, ethambutol, cycloserine, co-trimoxazole, and levoﬂoxacin
plus delamanid, supplied under compassionate use as last resort.
Acid-fast bacilli became undetectable by microscopy on three
consecutive sputum smears performed in the Swiss national
reference laboratory in Zu¨rich, Switzerland, in June 2014, but
1 month later, sputum smears reverted back to positive. The
decision was made to perform a surgical lobectomy. A
Mycobacterium tuberculosis isolate was recovered from the resected
tissue in August 2014 and sent to the World Health Organization
supranational reference laboratory in Munich-Gauting, Germany,
for susceptibility testing of delamanid.
There, 104 bacteria of the patient’s isolate (GB4492-175)
inoculated in duplicate on Middlebrook 7H11 agar containing
delamanid at the critical concentration of 0.2 mg/L grew on
average 104 cfu after 4 weeks of incubation at 378C, whereas a mean
of 98 cfu were counted on the control plate with 1% of the bacterial
inoculum (Table 1). Another isolate (CH-2014186009) from the
same patient recovered by the Swiss national reference
laboratory in February 2014 (sputum collection in January
2014), that is, right before the start of the delamanid-containing
regimen; the delamanid-susceptible M. tuberculosis reference
strain H37Rv; and a delamanid-resistant control strain obtained
by selective plating (kindly provided by Otsuka Novel Products
GmbH) yielded 0, 0, and .104 cfu, respectively, on drug-
containing medium. The minimal inhibitory concentrations
(MICs) of the two clinical isolates were determined in
mycobacteria growth indicator tubes (Becton Dickinson,
Heidelberg, Germany), following the protocol of Keller and
colleagues (7) with slight modiﬁcations, including the use of pure
substance powder (kindly provided by Otsuka Novel Products
GmbH) dissolved in dimethylsulfoxide. MIC was conﬁrmed in
the resazurin microtiter assay following a modiﬁed protocol of
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Martin and colleagues (8). Eight delamanid test concentrations
were applied in both systems (i.e., 0.016, 0.032, 0.063, 0.125, 0.25,
0.5, 1.0, and 2.0 mg/L). The MICs of isolates CH-2014186009 and
GB4492–175 were <0.016 and >2.0 mg/L, respectively, in both
mycobacteria growth indicator tubes and resazurin microtiter
assay, conﬁrming an at least 125-times higher MIC of the
resistant isolate compared with the susceptible one, which was
well below the epidemiological cutoff values and in the range of
MICs reported elsewhere for susceptible M. tuberculosis isolates
(0.006–0.024 mg/L) (7, 9, 10).
The genomes of isolates CH-2014186009 and GB4492-175
were sequenced at the Research Center Borstel, Germany, using
next-generation sequencing, as previously described, employing
the Nextera XT library preparation kit and the NextSEquation
500 instrument (both from Illumina, Eindhoven, the
Netherlands), reference mapping to the H37Rv genome
(GenBank ID: NC_000962.3), and variant detection using in-
house perl scripts (11). Whole-genome sequence data were
submitted as fastq ﬁles to the European Nucleotide Archive at the
European Bioinformatics Institute (Cambridge, UK) sequence
read archive (accession number ERP011090). For a detailed
phylogenetic classiﬁcation of the Beijing genotype isolates,
identiﬁed single nucleotide polymorphisms were cross-referenced
to a representative global dataset of M. tuberculosis Beijing
strains. The maximum likelihood analysis classiﬁed GB4492-175
as part of the “Asian ancestral 3” Beijing subgroup, which we
recently deﬁned as not highly associated with drug resistance (11).
Further comparative analysis to the most closely related, fully
susceptible Beijing strain within this cluster allowed us to
differentiate 1,782 genetic background polymorphisms from
384 variants speciﬁc for the patient’s isolates. Among those, we
found a series of mutations known to cause resistance to various
drugs, including the previously described mutation Rv0678 2
T.C conferring clofazimine/bedaquiline cross-resistance
(Table 2) (5, 6).
Direct genome comparison of the two isolates from our patient
revealed that phenotypic delamanid resistance arose together with
11 new genetic polymorphisms in isolate GB4492-175, which were
absent in the delamanid-susceptible isolate recovered before
initiation of delamanid treatment. The most likely variant
conferring delamanid resistance was mutation FbiA D49Y (Table 1);
the other variants were supposedly coselected after applying the
Table 1. Results of Delamanid Susceptibility Testing, Minimal Inhibitory Concentrations, and Resistance Genotype of fbiA
Isolate Time of Recovery Delamanid 1% Control 0.2 mg/L DLM MIC* fbiA Genotype
CH-2014186009 Feb 2014 (before DLM therapy) Sensitive 143 cfu 0 cfu <0.016 fbiA R175H
GB4492-175 Aug 2014 (after DLM treatment failure) Resistant 98 cfu 104 cfu >2.0 fbiA D49Y R175H
Definition of abbreviations: cfu = colony-forming units in the proportional method; DLM= delamanid; MIC =minimal inhibitory concentration.
*Determined in mycobacteria growth indicator tubes, confirmed by resazurin microtiter assay (for details, see text). The isolate recovered before
prescription of the delamanid-containing regimen was susceptible with very low MIC values, whereas the one recovered after treatment failure of the
respective regimen was resistant with at least 1253 higher MIC values.
Table 2. Drug Resistances, Minimal Inhibitory Concentrations, and Resistance Genotypes for Isolate GB4492-175 Recovered in
August 2014 after Treatment Failure of the Delamanid-Containing Regimen
Antituberculosis Drug
Isolate GB4492-175
DST Phenotype MIC (mg/L)
Resistance-associated
Polymorphism
Isoniazid Resistant — KatG S315T
Rifampicin Resistant >4.0* RpoB S450L
Ethambutol Resistant >4.0* EmbB D328Y
Streptomycin Resistant >1.0* S12 RpsL K88R
Pyrazinamide — — PncA E107Stop†
Oﬂoxacin Resistant —
GyrA D94YMoxiﬂoxacin Resistant >2.0*
Amikacin Susceptible —
Capreomycin Resistant — TlyA A17E†
Prothionamide Resistant — EthA 1047fs†
Bedaquiline NA 0.5‡ Rv0678 M1AClofazimine Resistant —
Linezolid Resistant rrl 2,814 g/tx
Definition of abbreviations: DST = drug susceptibility testing; MIC =minimal inhibitory concentration; NA = not applicable because of missing thresholds.
Dash indicates not determined.
*Determined by resazurin microtiter assay after the protocol of Martin and colleagues, with minor modifications (8).
†Several amino acid exchanges of the enzyme known to be associated with resistance phenotypes, but this particular variant has so far not been further
characterized or reported.
‡Determined with pure substance in mycobacteria growth indicator tubes after the protocol of Keller and colleagues, with minor modifications (7).
xDetected as heteroresistance.
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delamanid-containing regimen (see Table E1 in the online
supplement). Of note, both isolates also harbored variant FbiA
R175H, and we cannot completely exclude possible synergies
between both FbiA variants.
FbiA and the related gene products FbiB and FbiC are
involved in the biosynthetic pathway of the ﬂavin cofactor F420.
FbiC catalyzes the synthesis of F0, which FbiA and FbiB together
modify further to F420 (12, 13). Delamanid constitutes an inactive
prodrug and is supposed to be metabolized by the F420-dependent
nitroreductase Ddn (Rv3547) into its active form (10). F420 is
recycled into the reduced form by a glucose-6-phosphate
dehydrogenase (Fgd1).
Any mutation in one of these genes may lead to resistance to
delamanid (10). Mutations of ddn and/or fgd1 have already been
reported to be associated with resistances to delamanid and PA-
824, a closely related nitroimidazole-oxazine drug, respectively,
but one that only rarely occurs (9, 14). Likewise, mycobacterial
strains with mutated fbiA or fbiB were shown to lack coenzyme
F420 and to be resistant to PA-824 (15). FbiA (homolog synonym
cofD) is highly conserved among archeal and bacterial organisms
that are known to produce F420. Although D49 is not involved in
substrate binding, the amino acid position is highly conserved
(16). The data support the hypothesis that the identiﬁed D49Y
mutation of fbiA causes delamanid resistance. In vitro frequencies
of spontaneous delamanid resistance are comparable to those of
isoniazid, that is, ranging from 1/106 to 1/105
M. tuberculosis organisms (10).
Our case illustrates how rapidly bacterial resistance may
counteract the positive impulses given by the advent of new anti-TB
drugs, as long as those are not imbedded in efﬁcient concepts of
drug, patient, and infection control measures. The surprisingly rapid
development of resistance observed even toward the newest
compounds available underlines the need of systematic surveillance
of drug resistance toward new anti-TB drugs, allowing for
immediate actions on the emergence of resistance to prevent rapid
neutralization of the potentials that new drugs bring along to help
combat the MDR-TB epidemic. n
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An Important Step Forward, but Still a Way to Go
To the Editor:
Since the publication of the American Thoracic Society/European
Respiratory Society/Japanese Respiratory Society/Latin American
Thoracic Association evidence-based guidelines in 2011 (1),
signiﬁcant advances have been made in idiopathic pulmonary
ﬁbrosis (IPF), leading to a recently published update (2). Although
this represents a major step forward, some important questions
remain unanswered.
In our view, the main weakness of the guideline document relates
to the same level of recommendation (e.g., conditional
recommendation for use) given to antiacid therapy (regardless of the
presence or absence of symptomatic reﬂux) as to antiﬁbrotic agents
(e.g., pirfenidone and nintedanib) despite different levels and quality of
evidence. Only observational/retrospective studies and post hoc
analysis of patients randomly assigned to placebo in clinical trials of
pharmaceutical interventions are available for antiacid therapy
compared with large phase 3 randomized controlled trials for
antiﬁbrotic drugs. Despite the editor’s note added to the guideline, we
are seriously concerned that the recommendation on antiacid therapy
may be perceived as equivalent to other conditional recommendations
that are based on much stronger evidence. This paradox may be
partly a result of the methodology used. According to international
standards for guideline development, and to balance the need to
minimize bias with the need for expertise to inform decisions, only
panel members without conﬂicts of interest were allowed to discuss,
formulate, grade, and vote on the recommendations. Conversely,
in the previous version of the guidelines, both conﬂicted and
nonconﬂicted members participated without restriction in all the key
steps of the process. We speculate that many of the conﬂicted experts
would possibly have not given a conditional recommendation for use
of antiacid therapy because of insufﬁcient evidence.
Furthermore, some crucial questions remain unanswered
because of a lack of evidence in several areas in which research is
utterly needed. There is no doubt that pirfenidone and nintedanib
slow disease progression in patients with FVC more than 50%
predicted and diffusing capacity of the lung for carbon monoxide
more than 30% predicted, but what the effect is in patients with IPF
with more advanced disease is unknown. Pirfenidone and
nintedanib did not show an effect on quality of life, probably because
of the suboptimal tools available to measure this outcome in IPF.
Combination therapy, successfully used in other complex disorders
such as pulmonary arterial hypertension, would target multiple
proﬁbrotic pathways and is potentially the next step in IPF
therapy (3); however, safety, efﬁcacy, and cost issues need to be
carefully evaluated as a priority. Furthermore, despite the conditional
recommendation against the use of some drugs for treatment of
pulmonary arterial hypertension, further research is needed to
determine whether this is a useful target for treatment in IPF.
Progress is also needed to treat patients with progressive lung ﬁbrosis
other than IPF, such as chronic hypersensitivity pneumonitis,
connective tissue disease–associated interstitial lung disease, and
ﬁbrotic nonspeciﬁc interstitial pneumonia, by setting up speciﬁc
trials to assess whether the efﬁcacy of the novel antiﬁbrotic
compounds also extends to these conditions.
Several challenges also remain in the diagnostic process of IPF
(not addressed in the 2015 update). The 2011 guidelines provide a
useful framework for diagnosis, which, however, is mainly
applicable to clinical trials rather than to clinical practice. In many
patients, high-resolution computed tomography does not show a
deﬁnite usual interstitial pneumonia pattern, and according to the
guidelines, conﬁrmatory surgical lung biopsy should be considered
(1). Yet this is often not possible because of severe functional
impairment, comorbidities, or patient preferences. The role of less
invasive biopsy procedures such as transbronchial cryobiopsy (4)
should also be further evaluated. Alternative/additional criteria are
needed to formulate a secure diagnosis in those patients who are
likely to have IPF (those with possible usual interstitial pneumonia
pattern on computed tomography), but in whom no histologic data
are available and whose disease currently remains unclassiﬁed (5). n
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